Zonisamide is a sulfonamide that exhibits antiepileptic/anticonvulsant and neuroprotective activity and is clinically used to prevent seizures and epilepsy. Zonisamide inhibits carbonic anhydrase, voltage-gated Na+ channels, and T-type Ca2+ channels, and modulates release of GABA and glutamate. In animal models of Parkinson’s disease, zonisamide delays neurodegeneration.
| Cas No. | 68291-97-4 |
|---|---|
| Purity | ≥96% |
| Formula | C8H8N2O3S |
| Formula Wt. | 212.23 |
| Chemical Name | 1,2-Benzisoxazole-3-methanesulfonamide |
| IUPAC Name | 1,2-benzoxazol-3-ylmethanesulfonamide |
| Synonym | AD-810, CI-912, Excegran |
| Melting Point | 160-163°C |
| Solubility | Sparingly soluble in water. Soluble in methanol, ethanol, DMSO. |
| Appearance | White crystalline powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet | |
| Brochures |
Arawaka S, Fukushima S, Sato H, et al. Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease. PLoS One. 2014 Feb 20;9(2):e89076. PMID: 24586512.
Aggarwal M, Kondeti B, McKenna R. Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat. 2013;23(6):717-24. PMID: 23514045.
Holder JL Jr, Wilfong AA. Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2011 Nov;12(16):2573-81. PMID: 21967409.
Baulac M, Leppik IE. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res. 2007 Jul;75(2-3):75-83. PMID: 17553670.
